Consensus Insulet Corporation Sao Paulo

Equities

P2OD34

BRP2ODBDR009

Market Closed - Sao Paulo Other stock markets 12:54:31 2024-06-24 pm EDT			5-day change	1st Jan Change
36.66 ^BRL	+14.35%		-.--%	-24.41%

Jun. 24	Transcript : Insulet Corporation - Special Call
Jun. 22	Insulet Corporation Announces SECURE-T2d Pivotal Trial Results Demonstrate Omnipod 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes	CI

Evolution of the average Target Price on Insulet Corporation

Price target over the last 5 years

History of analyst recommendation changes

e54b36240557e.LEIX6devlSojVoxgx2FKvIm_xsG4jiMFjz81Qha0Zts.YTpbhq__7Wx0HtkijxI8zsLZ9JD62nFg9wlWIXzTUKtBFl3R7-LjU2kswQ~e3e4a52ef4966d397605afeac45c5f08

Analyst Recommendations on Insulet Corporation

Insulet Insider Sold Shares Worth $299,940, According to a Recent SEC Filing	Jun. 17	MT
Insulet Insider Sold Shares Worth $405,806, According to a Recent SEC Filing	Jun. 11	MT
Insulet Insider Sold Shares Worth $1,333,570, According to a Recent SEC Filing	Jun. 11	MT
Redburn Atlantic Initiates Insulet With Buy Rating, $235 Price Target	May. 30	MT
Insulet Insider Sold Shares Worth $596,970, According to a Recent SEC Filing	May. 29	MT
Insulet Shares Rise Despite Blue Orca's Short Position	May. 14	MT
Raymond James Adjusts Price Target on Insulet to $213 From $218	May. 10	MT
Wolfe Research Raises Price Target on Insulet to $205 From $200	May. 10	MT
Canaccord Genuity Adjusts Price Target on Insulet to $234 From $226	May. 10	MT
Jefferies Raises Price Target on Insulet to $260 From $255	May. 10	MT
Stifel Adjusts Price Target on Insulet to $185 From $208	May. 10	MT
Wolfe Upgrades Insulet to Outperform From Peerperform With $200 Price Target	May. 07	MT
Wolfe Research Upgrades Insulet to Outperform From Peer Perform, Price Target is $200	May. 07	MT
Barclays Trims Insulet Price Target to $213 From $214, Maintains Equal Weight Rating	Feb. 26	MT
ANALYST RECOMMENDATIONS : Abbvie, Microsoft, Tesla, Alphabet, Booking...	Feb. 05
UBS Raises Insulet Price Target to $211 From $175, Maintains Neutral Rating	Jan. 22	MT
Baird Upgrades Insulet to Outperform From Neutral, Raises Price Target to $238 From $180	Dec. 21	MT
ANALYST RECOMMENDATIONS : Amgen, Eli Lilly, Micron Salesforce, Texas Instruments...	Dec. 21
Morgan Stanley Upgrades Insulet to Overweight From Equalweight, Raises Price Target to $234 From $185	Dec. 04	MT
ANALYST RECOMMENDATIONS : Adobe, Broadcom, Comcast, Fair Isaac, Salesforce...	Dec. 04
ANALYST RECOMMENDATIONS : Boeing, Datadog, Estee Lauder, Qualcomm, Snowflake...	Nov. 28
ANALYST RECOMMENDATIONS : Apple, ADP, Fortinet, General Motors, S&P...	Nov. 03
BofA Slashes Price Target on Insulet to $180 From $295, Keeps Buy Rating	23-10-18	MT
Jefferies Upgrades Insulet to Buy From Hold	23-10-02	MT
ANALYST RECOMMENDATIONS : Amgen, Best Buy, Comcast, Fedex, Mosaic...	23-10-02

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

201.4 USD

Average target price

233.6 USD

Spread / Average Target

+16.01%

High Price Target

270 USD

Spread / Highest target

+34.07%

Low Price Target

185 USD

Spread / Lowest Target

-8.14%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Insulet Corporation

Redburn Atlantic
Raymond James
Wolfe Research
Canaccord Genuity
Jefferies & Co.
Stifel Nicolaus
Barclays
UBS
Baird
Morgan Stanley
BofA Securities
Citigroup
Piper Sandler
BTIG
Baptista Research
JPMorgan Chase
SVB Leerink
Oppenheimer
Berenberg Bank
Cowen

Ratings for Insulet Corporation

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar